推荐产品
品質等級
化驗
≥98% (HPLC)
形狀
liquid
製造商/商標名
Calbiochem®
儲存條件
OK to freeze
avoid repeated freeze/thaw cycles
protect from light
運輸包裝
dry ice
儲存溫度
−70°C
InChI
1S/C24H26FNO4.Na/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30;/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30);/q;+1/p-1/b12-11+;/t18-,19-;/m0./s1
InChI 密鑰
ZGGHKIMDNBDHJB-RPQBTBOMSA-M
一般說明
A synthetic, competitive inhibitor of HMG-CoA reductase that acts as anti-hypercholesterolemic agent. Unlike Lovastatin (Cat. No. 438185), Mevastatin (Cat. No. 474700), and Simvastatin (Cat. No. 567020), it does not require activation prior to use for in vitro studies. Reduces the basal MMP-1 levels in culture media of endothelial cells in a time- and dose-dependent manner. Fluvastatin is metabolized in the liver, primarily via hydroxylation of the indole ring at the 5- and 6-positions. N-Dealkylation and β-oxidation of the side-chain also occurs. The hydroxy metabolites are also reported to have some pharmacologic activity.
生化/生理作用
Reversible: yes
包裝
Packaged under inert gas
警告
Toxicity: Standard Handling (A)
外觀
A 10 mM (10 mg/2.13 ml) solution of Fluvastatin, Sodium Salt (344095) in H₂O.
其他說明
Yamamoto, A., et al. 2001. J. Pharm. Pharmacol.53, 227.
Dansette, P.M., et al. 2000. Exp. Toxicol. Pathol.52, 145.
Ikeda, U., et al. 2000. Hypertension36, 325.
Levy, R.I., et al. 1993. Circulation87 (4 Suppl.), III45.
Tse, F.L.S. et al. 1992. J. Clin. Pharmacol.32, 630.
Yuan, J., et al. 1991. Atherosclerosis87, 147.
Dansette, P.M., et al. 2000. Exp. Toxicol. Pathol.52, 145.
Ikeda, U., et al. 2000. Hypertension36, 325.
Levy, R.I., et al. 1993. Circulation87 (4 Suppl.), III45.
Tse, F.L.S. et al. 1992. J. Clin. Pharmacol.32, 630.
Yuan, J., et al. 1991. Atherosclerosis87, 147.
法律資訊
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
儲存類別代碼
12 - Non Combustible Liquids
水污染物質分類(WGK)
WGK 2
閃點(°F)
Not applicable
閃點(°C)
Not applicable
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门